NTRC reaches new milestones in their drug discovery programs and expands business development activities
Oss, 6 February 2014 – NTRC B.V. today announced that it has progressed its small molecule kinase inhibitor projects in oncology and immunology to the next phase of pre-clinical development. To support the out-licensing and partnering of these programs, Gavin D Clark, BSc CLP, has been appointed as Vice President Business Development.
Gavin has more than 30 years of experience in the pharmaceutical industry, including commercial positions at Janssen Pharmaceutica, Bayer and Novartis. Previously, he has been responsible for Global Infectious Diseases Licensing at GlaxoWellcome and VP Business Development at Tibotec Pharmaceuticals. Since 2002 Clark has consulted in commercial roles for various biotech companies, facilitating a number of important licensing deals in Europe, the US and Asia.
Clark is a Certified Licensing Professional (CLP) as accredited by the Licensing Executives Society North America.
NTRC is a privately owned biotech company based at the Pivot Park in Oss, The Netherlands. NTRC translates novel ideas for the treatment of human disease into small molecule drug candidates using its proprietary technology platforms Oncolines™, SynergyFinder™, ResidenceTimer™ and EntropySelect™. For more information on the drug discovery activities of NTRC, or NTRC Services, see the website of NTRC: www.ntrc.nl, or send an e-mail to firstname.lastname@example.org